Results 91 to 100 of about 1,149,511 (200)

Ipsilateral lung dose volume parameters predict radiation pneumonitis in addition to classical dose volume parameters in locally advanced NSCLC treated with combined modality therapy

South Asian Journal of Cancer, 2014
Purpose: The purpose was to determine the correlation of clinical factors and lung dose volume parameters with significant radiation pneumonitis (RP) in non-small cell lung cancer patients treated with combined modality therapy.
Sushma Agrawal, Sunil Kumar, Able Lawrence, Maria K. J. Das, Shaleen Kumar   +4 more
doaj   +1 more source

Organoids in Precision Radiotherapy: Methodological Foundations, Tumor‐Specific Evidence, and Translational Roadmaps

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background Radiotherapy remains a cornerstone of cancer treatment, while its efficacy is often limited by tumor radioresistance and the risk of normal tissue toxicity. Conventional preclinical models, including two‐dimensional (2D) cell cultures and murine xenografts, exhibit significant limitations in recapitulating human tumor ...
Yixian Zhu, Yawei Jiao, Jiao Xue, Xiaoli Lv, Songbing Qin   +4 more
wiley   +1 more source

University of California Radiation Laboratory Reports UCRL-1610

, 1951
Quarterly summary report of studies conducted through the Radiation Laboratory, University of California.
University of California. Radiation Laboratory.
core  

Circulating thrombomodulin during radiation therapy of lung cancer

, 1999
The endothelial cell glycoprotein, thrombomodulin (TM), is an important physiological anticoagulant. TM is downregulated and released from the cell membrane into the circulation by ionizing radiation and during inflammation.
Hauer-Jensen, Martin, Fink, Louis M., Kong, Feng Ming, Anscher, Mitchell S.   +3 more
core   +1 more source

PD‐L1 in Ovarian Cancer: Immune Evasion, Tumor‐Intrinsic Signaling, and Chemoresistance

Cancer Medicine, Volume 15, Issue 9, September 2026.
The “Dual Shield” model of PD‐L1 in ovarian cancer. On the outside, PD‐L1 engages PD‐1 to inactivate T cells and drive immune evasion (immune shield). Inside the tumor cell, PD‐L1 activates AKT–mTOR, enhances DNA repair, rewires metabolism, supports autophagy, and enforces stemness programs—collectively creating a chemoresistance shield.
Zhiyang Xu, Xiaohui Lv, Yunping Wang, Yanjie Ren   +3 more
wiley   +1 more source

University of California Radiation Laboratory Reports UCRL-1632

, 1952
Quarterly summary report of studies conducted through the Radiation Laboratory, University of California.
University of California. Radiation Laboratory.
core  

Efficacy and Safety of Initial Low‐Dose, Extended‐Interval Nivolumab Monotherapy in a 91‐Year‐Old Patient With Locally Advanced NSCLC and Poor Performance Status: A Case Report

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT The incidence of non‐small cell lung cancer (NSCLC) increases with age, with approximately half of the cases diagnosed in individuals aged 70 and older. In numerous clinical trials, immune checkpoint inhibitors (ICIs) have demonstrated significant efficacy in treating NSCLC without driver gene mutations.
Dan Kou, Xiang Yan, Qi Huang, Jingye Zhong, Qiongcheng Chen, Tao Zhao, Xianhua Xu   +6 more
wiley   +1 more source

First‐Line PD‐1 Inhibitor‐Based Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Revised Systematic Review and Meta‐Analysis of Phase III Trials

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background and Purpose Immune checkpoint blockade has changed the first‐line treatment landscape for advanced esophageal squamous cell carcinoma (ESCC), but the magnitude and consistency of benefit across phase III trials require careful synthesis.
Vincent Rothweiler, Christoph Roderburg, Muemtaz Koeksal, Björn Erik Ole Jensen, Torsten Feldt, Ilyas Gencer, Johannes C. Fischer, Wilfried Budach, Wolfram Trudo Knoefel, Guangyu Lu, Edwin Bölke   +10 more
wiley   +1 more source

TRAIL agonists rescue mice from radiation-induced lung, skin, or esophageal injury

The Journal of Clinical Investigation
Radiotherapy can be limited by pneumonitis, which is impacted by innate immunity, including pathways regulated by TRAIL death receptor DR5. We investigated whether DR5 agonists could rescue mice from toxic effects of radiation and found that 2 different ...
Jillian Strandberg, Anna Louie, Seulki Lee, Marina Hahn, Praveen Srinivasan, Andrew George, Arielle De La Cruz, Leiqing Zhang, Liz Hernandez Borrero, Kelsey E. Huntington, Payton De La Cruz, Attila A. Seyhan, Paul P. Koffer, David E. Wazer, Thomas A. DiPetrillo, Stephanie L. Graff, Christopher G. Azzoli, Sharon I. Rounds, Andres J. Klein-Szanto, Fabio Tavora, Evgeny Yakirevich, Abbas E. Abbas, Lanlan Zhou, Wafik S. El-Deiry   +23 more
doaj   +1 more source

Immunotherapeutic Approaches to Head and Neck Squamous Cell Carcinoma: Current Clinical Practice and Future Directions

Head &Neck, Volume 48, Issue 9, Page 2584-2592, September 2026.
ABSTRACT Background Head and neck squamous cell carcinoma (HNSCC) is frequently diagnosed at advanced stages and has historically been associated with poor outcomes. Immune checkpoint inhibition has transformed the therapeutic landscape, offering durable responses in recurrent, metastatic, and locally advanced disease.
Carol R. Bradford, Sreeram M. P., Karthik N. Rao, Orlando Guntinas‐Lichius, Nabil Saba, Alfio Ferlito   +5 more
wiley   +1 more source